reviewTop 10% cited
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Leukemia · 2009 · Vol. 24(1) · pp. 22–32
Hang Quach✉(Peter MacCallum Cancer Centre)David Ritchie(Peter MacCallum Cancer Centre)A. Keith Stewart(Mayo Clinic in Arizona)Paul J. Neeson(Peter MacCallum Cancer Centre)Simon J. Harrison(Peter MacCallum Cancer Centre)Mark J. Smyth(Peter MacCallum Cancer Centre)H. Miles Prince(University of Melbourne)
Multiple Myeloma Research and TreatmentsCancer therapeutics and mechanismsCancer Mechanisms and TherapyThalidomideIn vivoMultiple myelomaIn vitroImmune systemMechanism of actionDownregulation and upregulationMechanism (biology)Cancer researchPharmacology
MeSH terms
Anti-Inflammatory AgentsAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsHumansImmunologic FactorsKiller Cells, NaturalLymphocyte ActivationMultiple MyelomaOsteoclastsThalidomideAngiogenesis InhibitorsT-Lymphocytes, RegulatoryForkhead Transcription Factors
Funding
- Celgene
Citations
580
FWCI
11.63
field-weighted impact
References
96
Percentile
99%
vs. same field & year
Citations per year
References
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Nature reviews. Cancer · 2005 · 2,032 citations
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
Leukemia · 2001 · 555 citations
Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production
Bioorganic & Medicinal Chemistry Letters · 1999 · 338 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.